Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of Myofascial Release With and Without Taping in Patient With Heel Spur: (MFR-Taping)

14. mai 2026 oppdatert av: Sehrish Shahzad, Green International University

Effect of Myofascial Release With and Without Taping in Patient With Heel Spur: A Randomized Controlled Trial

The current study is a randomized controlled trial comparing the effectiveness of myofascial release therapy used alone versus myofascial release combined with clinical taping for individuals with heel spurs. The trial aims to evaluate improvements in pain, foot function, and overall disability. Interventions will be delivered twice weekly for a specified duration. The primary outcome is pain reduction, while secondary outcomes include improved foot function and reduced disability. The hypothesis is that the combination of myofascial release and taping will result in significantly greater clinical improvements compared to myofascial release alone.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Heel spur is a common musculoskeletal condition often associated with chronic plantar heel pain and functional limitations. This study will evaluate the added value of clinical taping when used in conjunction with Myofascial Release (MFR) therapy. Combining these approaches may offer a complementary effect by addressing both the soft tissue restrictions through manual therapy and providing mechanical support and proprioceptive feedback via taping. The trial uses a randomized controlled design to compare two intervention groups. Participants diagnosed with heel spurs will be randomly assigned to either the experimental group or the comparison group. The experimental group will receive standardized Myofascial Release sessions focusing on the plantar fascia and posterior chain musculature, followed by the application of therapeutic taping. The comparison group will receive the Myofascial Release protocol alone. Both interventions will be provided for a set duration, with sessions occurring twice per week. The study aims to investigate whether the addition of taping results in greater improvements in pain intensity, foot function, and overall disability. Outcome measures, including pain scales and functional assessment tools, will be assessed at baseline and at the conclusion of the treatment period. The trial will be carried out at clinics in Lahore to ensure standardized procedures and consistent delivery across sessions.

Studietype

Intervensjonell

Registrering (Faktiske)

38

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan
        • Green International University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Age 30-40 years
  • Both males and females
  • Clinically or radiographically confirmed heel spur
  • Pain intensity ≥ 3 on Visual Analog Scale
  • Symptom duration ≥ 4 weeks
  • Able to attend treatment sessions 3 times per week
  • Able to provide informed consent

Exclusion Criteria:

  • Previous foot or heel surgery
  • Current physiotherapy treatment for heel pain
  • Neurological disorders (e.g., neuropathy, radiculopathy)
  • Systemic inflammatory diseases (e.g., rheumatoid arthritis, gout)
  • Severe musculoskeletal deformities of the foot
  • Open wounds, skin infection, or allergy to tape
  • Corticosteroid injection in the last 3 months
  • Pregnancy
  • Any medical condition preventing safe participation

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Myofascial Release with Clinical Taping
Participants in this arm will receive a combination of myofascial release therapy and clinical taping. Myofascial release will be applied to the plantar fascia and the posterior chain muscles. Following the manual therapy, clinical taping (such as Kinesiology tape or rigid tape, depending on your specific protocol) will be applied to the affected foot to provide mechanical support and proprioceptive feedback. Sessions will be conducted twice weekly.
Annen: Myofascial Release with Clinical Taping
Participants will receive a 45-minute intervention session. The integrated components consist of manual myofascial release techniques followed by the application of clinical taping to the affected foot.
Andre navn:
  • Group A Intervention
Aktiv komparator: Myofascial Release Alone
Participants in this arm will receive the standardized myofascial release protocol only. The therapy will target the plantar fascia and surrounding soft tissues to reduce restrictions and pain. No clinical taping or additional manual interventions will be applied. Sessions will be conducted twice weekly to match the frequency of the experimental group
Annen: Myofascial Release Alone
Participants will receive the same 30 minutes of specialized myofascial release (MFR) manual therapy targeting the plantar fascia and calf musculature. No clinical taping will be applied. Sessions will be conducted twice weekly to ensure a consistent treatment frequency with the experimental group.
Andre navn:
  • Group B Intervention

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain Intensity
Tidsramme: Baseline and 4 weeks post-intervention.
Pain intensity will be measured using the Visual Analog Scale (VAS), where participants mark their pain level on a 100mm line ranging from "no pain" (0) to "worst imaginable pain" (100). Higher scores indicate greater pain intensity.
Baseline and 4 weeks post-intervention.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Foot Function
Tidsramme: Baseline and 4 weeks
The FFI will be used to assess changes in foot related functional limitations. The FFI evaluates pain, disability, and activity restriction related to foot conditions. Scores range 0 to 100, with high scores indicating greater impairment. This outcome will determine the improvement in functional ability following 4 weeks of Myofascial Release with or without taping.
Baseline and 4 weeks
Disability level
Tidsramme: Baseline and 4 weeks
The Disability subscale of the Foot Function index will measure the degree to which heel pain affects daily activities, including walking, standing, and mobility tasks. The score ranges from 0 to 100, with higher values reflecting greater disability. This outcome will evaluate the reduction in functional disability after the intervention period.
Baseline and 4 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Green International University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. april 2026

Primær fullføring (Faktiske)

29. april 2026

Studiet fullført (Faktiske)

6. mai 2026

Datoer for studieregistrering

Først innsendt

9. mai 2026

Først innsendt som oppfylte QC-kriteriene

9. mai 2026

Først lagt ut (Faktiske)

15. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • GIU/REC/26-27

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Only IPD used in the results publication will be shared.

IPD-delingstidsramme

It will be available after the completion of the study.

Tilgangskriterier for IPD-deling

Through the corresponding author.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere